| answer text |
<p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy
services will be in place by early 2020. The new model is designed to improve access
to specialist advice and care for patients, irrespective of where they live.</p><p>As
part of the new service, NHS England is establishing a National Haemoglobinopathy
Panel to provide national multidisciplinary oversight. Patients with complex needs,
wherever they live, will be able to be referred to the Panel for expert advice on
new treatments and approaches to care. The national service specification will also
include guidance for the 13 new born bloodspot screening programme laboratories to
refer infants found to be positive for sickle cell disease to the 10 new specialised
haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of
haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged
to link with and support community-based services provided through primary care or
community teams based within haemoglobinopathy teams.</p><p>The service specifications
for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating
centres are due to be established in the next month and the associated impact assessment
will be published as part of the suite of documents. The equality impact assessment
indicates that it will advance the promotion of equality and support the reduction
of health inequalities. For example, patients with thalassemia and sickle cell conditions
will have equitable access to high quality specialist care and support within specialised
commissioned centres irrespective of where in the country they live.</p><p>Hospital
Episode Statistics data is attached, showing finished admission episodes with a primary
and a primary or secondary diagnosis of sickle cell disorders by NHS England region
of residence and Index of Multiple Deprivation decile in the year 2017-18.</p>
|
|
